Go Deep
Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -45,122 | 32.3 | 87.31 | 15.18 | 10,665.29 |
| Oct 2026 | -45,422 | 32.5 | 87.83 | 15.18 | 10,634.86 |
| Oct 2026 | -37,194 | 32.1 | 86.67 | 15.18 | 10,439.52 |
| Oct 2026 | -40,252 | 34.2 | 92.37 | 15.18 | 11,091.77 |
| Oct 2026 | -42,172 | 33.4 | 96.08 | 15.18 | 11,538.72 |
| Oct 2026 | -42,313 | 35.6 | 96.34 | 15.18 | 11,540.07 |
| Oct 2026 | -42,555 | 35.8 | 96.86 | 15.18 | 11,615.01 |
| Oct 2026 | -43,310 | 36.4 | 98.34 | 15.18 | 11,792.31 |
| Oct 2026 | -43,497 | 36.5 | 98.70 | 15.18 | 11,806.69 |
| Oct 2026 | -43,371 | 36.4 | 98.47 | 15.18 | 11,755.43 |
Halozyme Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 480,999,000.0 | 376,708,000.0 | 451,767,000.0 | 354,264,000.0 |
| Net Profit | 229,913,000.0 | 150,049,000.0 | -141,591,000.0 | 175,225,000.0 |
| EPS | 2.0 | 1.3 | -1.2 | 1.5 |
Halozyme Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 1,396,611,000.0 | 1,015,324,000.0 | 829,253,000.0 | 660,116,000.0 | — |
| Net Profit | 316,889,000.0 | 444,091,000.0 | 281,594,000.0 | 202,129,000.0 | — |
| EPS | 2.6 | 3.5 | 2.1 | 1.5 | — |
Halozyme Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 2,525,323,000.0 | 2,063,477,000.0 | 1,733,270,000.0 | 1,841,511,000.0 | — |
| Total Liabilities | 2,476,509,000.0 | 1,699,656,000.0 | 1,649,462,000.0 | 1,671,713,000.0 | — |
| Total Equity | 48,814,000.0 | 363,821,000.0 | 83,808,000.0 | 169,798,000.0 | — |
Owes vs Owns
Halozyme Therapeutics, Inc. owed $0.94 for every $1 it owned in Jun 2026, up from $0.91 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.94× | 0.98× | 0.82× | 0.95× | 0.91× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Halozyme Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 5.7%Receivables 17.5%Inventory 7.0%Fixed assets (tangible) 3.3%Intangible assets 61.8%Other assets 4.8%
How it's funded — Dec 2025
Long-term debt 84.8%Payables 0.8%Other liabilities 12.4%Shareholders' equity 1.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 142.8 | 596.1 | 336.0 | 362.8 |
| Receivables | 441.3 | 308.5 | 234.2 | 231.1 |
| Inventory | 176.5 | 141.9 | 127.6 | 100.1 |
| Fixed assets (tangible) | 82.1 | 75.0 | 74.9 | 75.6 |
| Intangible assets | 1,561.8 | 818.7 | 889.7 | 955.7 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 120.8 | 123.4 | 70.8 | 116.3 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 13.3 |
| Long-term debt | 2,142.6 | 1,505.8 | 1,499.2 | 1,492.8 |
| Payables | 20.9 | 10.2 | 11.8 | 17.7 |
| Other liabilities | 313.0 | 183.6 | 138.4 | 147.9 |
| Shareholders' equity | 48.8 | 363.8 | 83.8 | 169.8 |
| Net tangible assets | -1,513.0 | -454.8 | -805.9 | -785.9 |
Halozyme Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 651,558,000.0 | 479,064,000.0 | 388,571,000.0 | 240,110,000.0 | — |
| Investing Activities | -545,813,000.0 | -262,723,000.0 | -96,909,000.0 | -487,005,000.0 | — |
| Financing Activities | -85,174,000.0 | -218,861,000.0 | -407,987,000.0 | 362,371,000.0 | — |